Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
The iShares U.S. Pharmaceuticals ETF (IHE) and the Invesco Biotechnology & Genome ETF (PBE) are two investment options that cater to different interests within the healthcare sector. IHE provides a more affordable way to gain exposure to major pharmaceutical companies, while PBE is geared towards high-growth biotech and genetic engineering firms.
Investors often find themselves at a crossroads when deciding between these ETFs. The healthcare sector presents a conundrum between the potential for high growth in biotech and the established revenue streams of pharmaceutical giants. Both ETFs offer targeted exposure, but they differ in their portfolio construction and historical volatility patterns.
When choosing between these two ETFs, investors must weigh their preference for specialized innovation versus larger pharmaceutical companies. Beta is a useful metric to consider, as it measures price volatility relative to the S&P 500. Beta is calculated based on the fund's monthly returns over its available history, which in this case is up to five years. The 1-year return represents the total return over the trailing 12 months, and the dividend yield is calculated from the trailing-12-month distribution yield.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
